CN108888601A - 一种维生素e硒微胶囊片剂、制备方法及其用途 - Google Patents
一种维生素e硒微胶囊片剂、制备方法及其用途 Download PDFInfo
- Publication number
- CN108888601A CN108888601A CN201810871551.3A CN201810871551A CN108888601A CN 108888601 A CN108888601 A CN 108888601A CN 201810871551 A CN201810871551 A CN 201810871551A CN 108888601 A CN108888601 A CN 108888601A
- Authority
- CN
- China
- Prior art keywords
- selenium
- vitamin
- tablet
- microcapsules
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title claims abstract description 131
- 229930003427 Vitamin E Natural products 0.000 title claims abstract description 65
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 239000011709 vitamin E Substances 0.000 title claims abstract description 65
- 235000019165 vitamin E Nutrition 0.000 title claims abstract description 65
- 229940046009 vitamin E Drugs 0.000 title claims abstract description 65
- 239000003094 microcapsule Substances 0.000 title claims abstract description 50
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 44
- 239000011669 selenium Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title abstract description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 26
- 239000011122 softwood Substances 0.000 claims abstract description 21
- 239000004375 Dextrin Substances 0.000 claims abstract description 19
- 229920001353 Dextrin Polymers 0.000 claims abstract description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 19
- 235000019425 dextrin Nutrition 0.000 claims abstract description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 19
- 235000000346 sugar Nutrition 0.000 claims abstract description 19
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 13
- 235000020985 whole grains Nutrition 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 7
- 235000013339 cereals Nutrition 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 206010039921 Selenium deficiency Diseases 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- 230000002000 scavenging effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 230000003647 oxidation Effects 0.000 abstract description 9
- 238000007254 oxidation reaction Methods 0.000 abstract description 9
- 150000003254 radicals Chemical class 0.000 abstract description 9
- 238000005469 granulation Methods 0.000 abstract description 7
- 230000003179 granulation Effects 0.000 abstract description 7
- 238000001035 drying Methods 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract 1
- 150000002978 peroxides Chemical class 0.000 description 8
- 230000003064 anti-oxidating effect Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 4
- -1 lipid free radical Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- XDSSPSLGNGIIHP-VKHMYHEASA-N Se-methyl-L-selenocysteine Chemical compound C[Se]C[C@H]([NH3+])C([O-])=O XDSSPSLGNGIIHP-VKHMYHEASA-N 0.000 description 1
- XDSSPSLGNGIIHP-UHFFFAOYSA-N Se-methyl-L-selenocysteine Natural products C[Se]CC(N)C(O)=O XDSSPSLGNGIIHP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明公开一种维生素E硒微胶囊片剂、制备方法及其用途,属于功能食品领域,所述微胶囊片剂组分包括L‑硒‑甲基硒代半胱氨酸、维生素E微胶囊(50%含量)、微晶纤维素、糖粉、糊精、硬脂酸镁、滑石粉。制备方法是,以L‑硒‑甲基硒代半胱氨酸、维生素E微胶囊(50%含量)为主要功能成分,其它辅助材料按照一定比例备料,经原料预处理、混合、制软材、造粒、干燥、整粒、压片等工艺步骤制成维生素E硒微胶囊片剂。该片剂具有明显的体、内外抗氧化自由基活性。
Description
技术领域
本发明属于功能食品技术领域,尤其涉及一种维生素E硒微胶囊片剂、制备方法及其用途。
背景技术
有机硒L-硒甲基硒代半胱氨酸(L-Se-methylselenocysteine,L-SeMC)是甲基化的硒代半胱氨酸,是一种新型的硒强化剂,具有类似谷胱甘肽过氧化物酶(GSH-Px)活性,发挥抗氧化作用。维生素E(Vitamin E,VE),又称生育酚,是一组具有生物活性的化学结构式近似的酚类化合物,是维持动物正常生殖机能,促进机体代谢,维护肌肉健康和抗氧化作用所必需的物质。L-SeMC和VE都有一定的抗氧化能力。
硒是人体生长发育必不可少的一种微量元素,硒是GSH-Px的成分,GSH-Px具有抗氧化功能,可防止有害自由基的形成及其对不饱和脂肪酸的进攻,催化过氧化物还原为乙醇,从而清除组织中有害的氢过氧化物,保护生物大分子和生物膜结构免受过氧化物损伤,其作用在于转化过氧化物为相关的醇类(或水)并能清除自由基。研究发现,随着硒浓度的变化GSH-Px的活性也发生变化,且酶活性变化总是滞后硒浓度的变化。硒缺乏时,该酶的活性降低,不能充分催化过氧化物引起脂质自由基和过氧化物的积累,以致对细胞膜和细胞壁产生过氧化损伤。
维生素E在膜脂质双层的集中分布使其能在脂质氧化的始发和延伸部位抑制脂质的氧化,因此可把维生素E作为自由基的清除剂。维生素E是一种非特异性的生物抗氧化剂,维生素E结合在细胞膜上使细胞免受自由基进攻和过氧化损伤,而硒通过GSH-Px等阻断自由基对机体的损伤,而且硒又是GSH-Px的必需成分。硒在保护细胞膜免受氧化方面,对维生素E起着补偿和协调的作用。硒还可通过谷胱甘肽过氧化物的不同功能,防御缺乏维生素E对肝脏的损害。所以硒和维生素E在抗氧化中起着协同作用。
维生素E是防止过氧化物生成的第一道防线,含硒的GSH-Px起着第二道防线的作用。维生素E和硒在防止过氧化损害方面具有互补作用。共同保护细胞膜的质膜结构的完整性。硒与维生素E的协同作用主要表现在:(1)硒可减少保护细胞膜所需的维生素E量;(2)硒是维持胰腺正常生理功能所必需的微量元素,胰腺分泌的胰蛋白酶、胰脂肪酶有助于脂肪的消化吸收,从而提高维生素E的吸收利用率;(3)血浆硒与血浆维生素E含量呈正相关,补硒有助于维持机体组织较高水平的维生素E;(4)维生素E可维持体内硒活性,减少机体硒损失;(5)维生素E是脂肪膜组分,可防止脂质氧化和活性氧化物(ROS)的产生,因此,在维生素E作用下清除ROS所需GSH-Px量减少,对硒需要量也随之减少。
虽然硒和维生素E在营养作用中有很多相似之处,具有相似的抗氧化作用,但二者不可相互替换,因为其发挥功能的部位不同,维生素E在细胞外起抗氧化作用,而硒则是在细胞内。
发明内容
针对上述问题,本发明的目的在于提供一种维生素E硒微胶囊片剂、制备方法及其用途。
本发明采用的技术方案如下:
一种维生素E硒微胶囊片剂,其特征在于:包括下列质量份数的原料:L-硒-甲基硒代半胱氨酸0.005-0.035份、维生素E微胶囊5-15份、微晶纤维素5-25份、糊精5-25份、糖粉10-30份、质量分数为3-15%的PVP水溶液1-3份、硬脂酸镁0.1-1份和滑石粉0.1-1份。
作为对上述方案的进一步优化,所述维生素E微胶囊中维生素E的质量分数为50%。
本发明还提供一种制备上述维生素E硒微胶囊片剂的方法,其按照下述步骤进行:
1)原料预处理:将L-硒-甲基硒代半胱氨酸、维生素E微胶囊、微晶纤维素、糊精、糖粉、硬脂酸镁和滑石粉分别粉碎后过60目~100目筛;再按照权利要求1所述的质量份数分别称取原料,备用;
2)混料:将经步骤1)过筛后的L-硒-甲基硒代半胱氨酸、维生素E微胶囊、微晶纤维素、糖粉和糊精混合均匀,制得混料;
3)造粒:将PVP水溶液缓慢喷洒在步骤2)所得混料上进行软材制作,然后用14目~20目的筛网造粒,制得湿粒;
4)干燥:将步骤3)所得湿粒均匀地摊放在托盘中,然后置于40℃~65℃真空干燥箱中干燥至水分含量为2%~8%;
5)整粒:将经步骤4)干燥的湿粒过18~24目筛网进行整粒,得整粒料;
6)压片:在步骤5)所得整粒料中加入硬脂酸镁和滑石粉,混合均匀,经压片机压片获得维生素E硒微胶囊片剂成品。
本发明还进一步公开一种药物组合物在抗氧化、自由基清除及硒缺乏营养保健中的用途,所述药物组合物包括上述的基料和助料。
本发明的有益效果:
本发明所提供的维生素E硒微胶囊片剂及其制备工艺能较好保持L-硒-甲基硒代半胱氨酸和维生素E的抗氧化活性,易于吸收。具有抗氧化清除自由基,阻止自由基对人体细胞破坏的功效,提高免疫力,保护人体器官和组织。其成品便于携带与保存,食用方便。制作工艺合理,操作简单,易于推广实施。
具体实施方式
下面通过具体的实施例对本发明的技术方案做进一步的解释说明。
实施例1
预先将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)、微晶纤维素、糊精、糖粉分别粉碎,过60目筛;将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)按照0.035:15的质量比例混合,然后加入质量比例为5:5:10的微晶纤维素:糊精:糖粉混匀,再加入质量比例为1的7.5%PVP水溶液搅拌均匀制备成软材(所述制备的软材达到的程度为用手紧握能成团,用手指压能裂开);制备的软材过14目筛网制粒,然后在40℃真空干燥箱中烘干,水分含量控制在2%,然后过18目筛网去除碎掉的部分。将造好的粒,加入质量比例为0.1:0.1的硬脂酸镁:滑石粉,充分混合,然后在压片机上压成微胶囊片。
实施例2
预先将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)、微晶纤维素、糊精、糖粉分别粉碎,过100目筛;将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)按照0.005:5的质量比例混合,然后加入质量比例为15:25:25的微晶纤维素:糊精:糖粉混匀,再加入质量比例为3的7.5%PVP水溶液搅拌均匀制备成软材(所述制备的软材达到的程度为用手紧握能成团,用手指压能裂开);制备的软材过20目筛网制粒,然后在65℃真空干燥箱中烘干,水分含量控制在8%,然后过24目筛网去除碎掉的部分。将造好的粒,加入质量比例为1:1的硬脂酸镁:滑石粉,充分混合,然后在压片机上压成微胶囊片。
实施例3
预先将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)、微晶纤维素、糊精、糖粉分别粉碎,过80目筛;将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)按照0.010:10的质量比例混合,然后加入质量比例为10:20:20的微晶纤维素:糊精:糖粉混匀,再加入质量比例为2的7.5%PVP水溶液搅拌均匀制备成软材(所述制备的软材达到的程度为用手紧握能成团,用手指压能裂开);制备的软材过18目筛网制粒,然后在50℃真空干燥箱中烘干,水分含量控制在6%,然后过20目筛网去除碎掉的部分。将造好的粒,加入质量比例为0.5:0.5的硬脂酸镁:滑石粉,充分混合,然后在压片机上压成微胶囊片。
实施例4
预先将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)、微晶纤维素、糊精、糖粉分别粉碎,过100目筛;将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)按照0.015:10的质量比例混合,然后加入质量比例为10:15:15的微晶纤维素:糊精:糖粉混匀,再加入质量比例为1.5的7.5%PVP水溶液搅拌均匀制备成软材(所述制备的软材达到的程度为用手紧握能成团,用手指压能裂开);制备的软材过16目筛网制粒,然后在45℃真空干燥箱中烘干,水分含量控制在2.5%,然后过20目筛网去除碎掉的部分。将造好的粒,加入质量比例为0.3:0.2的硬脂酸镁:滑石粉,充分混合,然后在压片机上压成微胶囊片。
实施例5
预先将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)、微晶纤维素、糊精、糖粉分别粉碎,过80目筛;将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)按照0.020:10的质量比例混合,然后加入质量比例为15:15:15的微晶纤维素:糊精:糖粉混匀,再加入质量比例为1.2的7.5%PVP水溶液搅拌均匀制备成软材(所述制备的软材达到的程度为用手紧握能成团,用手指压能裂开);制备的软材过18目筛网制粒,然后在50℃真空干燥箱中烘干,水分含量控制在3%,然后过18目筛网去除碎掉的部分。将造好的粒,加入质量比例为0.2:0.3的硬脂酸镁:滑石粉,充分混合,然后在压片机上压成微胶囊片。
实施例6
预先将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)、微晶纤维素、糊精、糖粉分别粉碎,过80目筛;将L-硒-甲基硒代半胱氨酸、维生素E微胶囊(50%含量)按照0.025:10的质量比例混合,然后加入质量比例为10:20:30的微晶纤维素:糊精:糖粉混匀,再加入质量比例为1.3的7.5%PVP水溶液搅拌均匀制备成软材(所述制备的软材达到的程度为用手紧握能成团,用手指压能裂开);制备的软材过18目筛网制粒,然后在60℃真空干燥箱中烘干,水分含量控制在3.5%,然后过18目筛网去除碎掉的部分。将造好的粒,加入质量比例为0.3:0.3的硬脂酸镁:滑石粉,充分混合,然后在压片机上压成微胶囊片。
对实施例1-6制备的成品进行评定。
一、对实施例1-6所得产品进行检验,结果见表1:
表1实施例1-6产品检验结果
二、体外抗氧化实验:
实施例1-6体外清除DPPH自由基结果见表2:
表2实施例1-6体外清除DPPH自由基结果
三、体内抗氧化实验:
动物分组:实验前将30只老鼠适应性喂养7d,随机分为三组,每组10只。维生素E硒微胶囊片剂低剂量组、高剂量组的药物剂量分别为相当于人体推荐量的10、20倍。维生素E硒微胶囊片剂粉碎成均匀粉末,分别精确称取片剂粉末257.60mg、517.60mg溶解于100mL的3%生理盐水-吐温80溶液。每10g的小鼠灌胃1.0mL,空白对照组喂同体积的3%生理盐水-吐温溶液。每天上午10点按各剂量组的要求灌胃,连续30d。末次给药后只饮水。24h后小鼠摘眼球取血,血液置于1.5mL离心管,3000r/min离心10min,分离的上清液即为血清,按试剂盒说明测SOD、GSH-Px的活性和T-AOC、MDA的含量。
体内抗氧化试验结果:
表3维生素E硒微胶囊片剂对小鼠血清中SOD含量的影响
表4维生素E硒微胶囊片剂对小鼠血清中GSH-Px含量的影响
表5维生素E硒微胶囊片剂对小鼠血清中T-AOC含量的影响
表6维生素E硒微胶囊片剂对小鼠血清中MDA含量的影响
通过上述检验结果可知,通过本发明制备的维生素E硒微胶囊片剂复合国家安全和卫生标准,L-硒-甲基硒代半胱氨酸和维生素E等有效成分的含量较高,损失较少;而且,通过体外抗氧化试验可知,其对体外DPPH自由基的清除率可达99%以上;进一步通过体内抗氧化试验可知,具有明显的抗氧化功效,所以,本发明所述片剂在抗氧化、自由基清除及硒缺乏营养保健具有显著作用。
值得一提的是,以上所述实施例仅为发明的较佳实施例而己,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (4)
1.一种维生素E硒微胶囊片剂,其特征在于:包括下列质量份数的原料:L-硒-甲基硒代半胱氨酸0.005-0.035份、维生素E微胶囊5-15份、微晶纤维素5-25份、糊精5-25份、糖粉10-30份、质量分数为3-15%的PVP水溶液1-3份、硬脂酸镁0.1-1份和滑石粉0.1-1份。
2.如权利要求1所述的一种维生素E硒微胶囊片剂,其特征在于:所述维生素E微胶囊中维生素E的质量分数为50%。
3.制备如权利要求1或2所述的一种维生素E硒微胶囊片剂的方法,其特征在于:按照下述步骤进行:
1)原料预处理:将L-硒-甲基硒代半胱氨酸、维生素E微胶囊、微晶纤维素、糊精、糖粉、硬脂酸镁和滑石粉分别粉碎后过60目~100目筛;再按照权利要求1所述的质量份数分别称取各原料,备用;
2)混料:将经步骤1)过筛后的L-硒-甲基硒代半胱氨酸、维生素E微胶囊、微晶纤维素、糖粉和糊精混合均匀,制得混料;
3)造粒:将PVP水溶液缓慢喷洒在步骤2)所得混料上进行软材制作,然后用14目~20目的筛网造粒,制得湿粒;
4)干燥:将步骤3)所得湿粒均匀地摊放在托盘中,然后置于40℃~65℃真空干燥箱中干燥至水分含量为2%~8%;
5)整粒:将经步骤4)干燥的湿粒过18~24目筛网进行整粒,得整粒料;
6)压片:在步骤5)所得整粒料中加入硬脂酸镁和滑石粉,混合均匀,经压片机压片获得维生素E硒微胶囊片剂成品。
4.一种药物组合物在抗氧化、自由基清除及硒缺乏营养保健中的用途,其特征在于:所述药物组合物包括权利要求1所述的原料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810871551.3A CN108888601A (zh) | 2018-08-02 | 2018-08-02 | 一种维生素e硒微胶囊片剂、制备方法及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810871551.3A CN108888601A (zh) | 2018-08-02 | 2018-08-02 | 一种维生素e硒微胶囊片剂、制备方法及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108888601A true CN108888601A (zh) | 2018-11-27 |
Family
ID=64353039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810871551.3A Pending CN108888601A (zh) | 2018-08-02 | 2018-08-02 | 一种维生素e硒微胶囊片剂、制备方法及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108888601A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109497562A (zh) * | 2018-12-26 | 2019-03-22 | 广东润源中天生物科技有限公司 | 一种富硒维生素e软胶囊及其制备方法 |
CN109805391A (zh) * | 2019-03-08 | 2019-05-28 | 上海萧雅生物科技股份有限公司 | 一种含有片剂和胶囊双重剂型的美白食品制剂及其服用方法 |
CN110833531A (zh) * | 2019-12-19 | 2020-02-25 | 健康元药业集团股份有限公司 | 一种维生素e制剂及其制备方法 |
CN113057332A (zh) * | 2021-03-19 | 2021-07-02 | 江苏大学 | 胶囊挤压式功能性食品3d打印材料及制备方法和用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1927188A (zh) * | 2006-08-25 | 2007-03-14 | 西南合成制药股份有限公司 | 一种耐压型维生素e微囊及其制备方法 |
CN101147730A (zh) * | 2006-09-22 | 2008-03-26 | 许宏昌 | 一种含硒、维生素e的木糖醇片的组成及其制造方法 |
CN104939075A (zh) * | 2015-05-26 | 2015-09-30 | 南昌大学 | 一种以l-硒甲基硒代半胱氨酸为主要原料的抗氧化保健品 |
CN107087784A (zh) * | 2017-06-26 | 2017-08-25 | 济源希健生物医药科技发展有限公司 | 一种包含l‑硒‑甲基硒代半胱氨酸的麦芽糊精的制作方法 |
CN107223986A (zh) * | 2017-06-26 | 2017-10-03 | 济源希健生物医药科技发展有限公司 | 一种富硒多肽保健品及其制备方法 |
-
2018
- 2018-08-02 CN CN201810871551.3A patent/CN108888601A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1927188A (zh) * | 2006-08-25 | 2007-03-14 | 西南合成制药股份有限公司 | 一种耐压型维生素e微囊及其制备方法 |
CN101147730A (zh) * | 2006-09-22 | 2008-03-26 | 许宏昌 | 一种含硒、维生素e的木糖醇片的组成及其制造方法 |
CN104939075A (zh) * | 2015-05-26 | 2015-09-30 | 南昌大学 | 一种以l-硒甲基硒代半胱氨酸为主要原料的抗氧化保健品 |
CN107087784A (zh) * | 2017-06-26 | 2017-08-25 | 济源希健生物医药科技发展有限公司 | 一种包含l‑硒‑甲基硒代半胱氨酸的麦芽糊精的制作方法 |
CN107223986A (zh) * | 2017-06-26 | 2017-10-03 | 济源希健生物医药科技发展有限公司 | 一种富硒多肽保健品及其制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109497562A (zh) * | 2018-12-26 | 2019-03-22 | 广东润源中天生物科技有限公司 | 一种富硒维生素e软胶囊及其制备方法 |
CN109805391A (zh) * | 2019-03-08 | 2019-05-28 | 上海萧雅生物科技股份有限公司 | 一种含有片剂和胶囊双重剂型的美白食品制剂及其服用方法 |
CN110833531A (zh) * | 2019-12-19 | 2020-02-25 | 健康元药业集团股份有限公司 | 一种维生素e制剂及其制备方法 |
CN113057332A (zh) * | 2021-03-19 | 2021-07-02 | 江苏大学 | 胶囊挤压式功能性食品3d打印材料及制备方法和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108888601A (zh) | 一种维生素e硒微胶囊片剂、制备方法及其用途 | |
CN102188565B (zh) | 一种减肥软胶囊及其制备方法 | |
JP7084139B2 (ja) | ブドウとブルーベリーの混合体を包含する特定の栄養組成物又は治療組成物 | |
CN106132425B (zh) | 包含柑橘类种子提取物的组合物、食品、药品和包含柑橘类种子提取物的组合物制造方法 | |
CN109007224A (zh) | 一种含有雨生红球藻虾青素调理女性机体的压片糖果及其制备方法 | |
Mirunalini et al. | Antioxidant potential and current cultivation aspects of an edible milky mushroom-Calocybe indica | |
CN111643531A (zh) | 一种复合型灵芝破壁孢子粉及其制备方法 | |
CN106036898A (zh) | 一种具有抗疲劳功效的组合物及制备方法和用途 | |
Adetuyi et al. | Banana peel as a source of nutraceuticals | |
Srivastava et al. | Dynamic bioactive properties of nutritional superfood Moringa oleifera: A comprehensive review | |
CN108497498A (zh) | 一种解酒护肝的功能性食品及其制备方法 | |
CN112493485A (zh) | 一种nmn抗衰老保健品及其制备方法 | |
WO2002011744A1 (fr) | Capsule renfermant des antioxydants de type opc (oligomeres procyanidoliques ) a base d'extrait de pepins de raisin et son procede de preparation | |
KR101478196B1 (ko) | 꾸지뽕을 주성분으로 하는 항산화 및 당뇨병 예방용 조성물 | |
CN105767969A (zh) | 一种苹果纤维醋糖果片及其制备方法 | |
CN105614861B (zh) | 金花葵榛子咀嚼片及其制备方法 | |
CN109043545A (zh) | 一种复合生物素营养制剂及其制备方法、应用 | |
CN102302104A (zh) | 番茄红素蜂花粉及制法 | |
CN106387352A (zh) | 一种含茶多酚的微胶囊动物免疫增强剂及其制备方法 | |
CN105918586A (zh) | 一种玛卡片的制作工艺 | |
ITTO20010028A1 (it) | Metodo per aumentare l'attivita' antitumorale di una sostanza contenente amigdalina, composizione contenente una sostanza con contenuto aume | |
CN109329937A (zh) | 一种含有角豆树果的组合物及其制备方法与应用 | |
CN104543817A (zh) | 蓝莓籽粉及其制备方法和应用 | |
DE102011052708A1 (de) | Verfahren zum Schutz photolabiler Wirkstoffe | |
TWI836896B (zh) | 萃取物用於製備提高粒線體活性的醫藥或非醫藥組合物的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181127 |
|
RJ01 | Rejection of invention patent application after publication |